Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

BACKGROUND: Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe immuno-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Gauthier, Martin, Durrieu, Françoise, Martin, Elodie, Peres, Michael, Vergez, François, Filleron, Thomas, Obéric, Lucie, Bijou, Fontanet, Quillet Mary, Anne, Ysebaert, Loic
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694602/
https://ncbi.nlm.nih.gov/pubmed/31412798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5971-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires